Immunotherapy for Melanoma in 2026: TIL Therapy, Vaccines, and Checkpoint Combos
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-05-15 · 10 min read
Stage IV melanoma is now curable for many. Tumor-infiltrating lymphocytes, mRNA vaccines, and new checkpoint inhibitors are rewriting outcomes.
Stage IV Melanoma Is No Longer a Death Sentence
In 2010, metastatic melanoma had a 5-year survival of 9%. In 2026, that number is 55%+ — and rising — thanks to layered immunotherapy.
2026 Treatment Arsenal
- Checkpoint inhibitors: ipilimumab + nivolumab (CheckMate-067 10-year data: 43% alive)
- TIL therapy: lifileucel (Amtagvi) — first FDA-approved cellular therapy for solid tumor
- mRNA personalized vaccine (Moderna mRNA-4157 + pembrolizumab): 49% reduction in recurrence
- LAG-3 inhibitor (relatlimab + nivolumab — Opdualag)
- Oncolytic viruses (TVEC, RP1)
What This Means
For newly diagnosed Stage III-IV melanoma patients, enrolling in a clinical trial combining personalized vaccines with checkpoint inhibitors offers the best outcomes.
Side Effects to Manage
Immune-related adverse events (irAEs) include pneumonitis — inflammation of the lungs that may require temporary oxygen therapy and steroids. Monitor for new cough or shortness of breath and report immediately.
See our mRNA cancer vaccines deep dive for the full vaccine landscape.